Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Drug Makers Switch To Reliance On Generics Sales

This article was originally published in PharmAsia News

Executive Summary

Several Japanese drug makers see greater opportunities in the generics market this year as major drugs begin losing patent protections. Some of the expirations are faced by Japanese makers themselves, including Daiichi Sankyo's bacteria fighter Cravit (levofloxacin) and Otsuka Pharmaceutical's ulcer treatment Mucosta (rebamipide). They, and AstraZeneca KK's cancer drug Casodex (bicalutamide) also losing its patent protection, boasted annual sales in the $500 million range. Sawai Pharmaceutical is set to take advantage of the expirations and a government emphasis on prescribing generics, with 34 generics set to be launched by the end of May. Towa Pharmaceutical plans 14 and Nichi-Iko Pharmaceutical 26. (Click here for more - a subscription may be required

You may also be interested in...

Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse

Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.

Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces

Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.

Global Pharma Guidance Tracker – November 2019

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts